ALNY Q1 2021 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$178M+78.5% YoY

Gross Profit

$147M82.5% margin

Operating Income

-$186M-104.9% margin

Net Income

-$200M-112.8% margin

EPS (Diluted)

$-1.71

QoQ Revenue Growth

+8.6%

Cash Flow

Operating Cash Flow

-$236M

Free Cash Flow

-$253M

Stock-Based Comp.

$56M

Balance Sheet

Total Assets

$3.3B

Total Liabilities

$2.3B

Stockholders' Equity

$926M

Cash & Equivalents

$380M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$178M	$99M	+78.5%
Gross Profit	$147M	$86M	+70.0%
Operating Income	-$186M	-$210M	+11.4%
Net Income	-$200M	-$182M	-9.9%

Revenue Segments

Product

$136M100%

Geographic Segments

Non-US Or Europe

$12M56%

Europe

$8M37%

UNITED STATES

$1M7%